Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 24, 2017
SOUTH PLAINFIELD, N.J. , Oct. 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7 at 1:35 pm MT .
Additional Formats
Oct 23, 2017
SOUTH PLAINFIELD, N.J. , Oct. 23, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on October 23, 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to eight new employees.
Additional Formats
Oct 19, 2017
SOUTH PLAINFIELD, N.J. , Oct. 19, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday, November 2, 2017
Additional Formats
Oct 12, 2017
- Concluded dose-finding part of SUNFISH study -
- Milestone triggers $20 million payment to PTC from Roche -
Additional Formats
Oct 03, 2017
- Data presented at the 22nd International World Muscle Society (WMS) Congress -
Additional Formats
Sep 21, 2017
SOUTH PLAINFIELD, N.J. , Sept. 21, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 18, 2017 it approved non-statutory stock options to purchase an aggregate of 32,500 shares of its common stock to thirteen new employees.
Additional Formats
Sep 07, 2017
- Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community
Additional Formats
Aug 10, 2017
SOUTH PLAINFIELD, N.J. , Aug. 10, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 7, 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to ten new employees.
Additional Formats
Aug 08, 2017
- Translarna™ second quarter sales of $45.8 M representing 197% growth over 2Q2016 -
- Over 1,200 patients on EMFLAZA™ 12 weeks into launch -
- ~400% dose-dependent increase in full length SMN2 mRNA shown in SUNFISH trial interim analysis -
- 2017 revenue guidance increased to $155-180 M -
Additional Formats
Jul 25, 2017
SOUTH PLAINFIELD, N.J. , July 25, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Tuesday, August 8, 2017 at
Additional Formats